Tumor heterogeneity: Morphological, molecular and clinical implications

Histology and Histopathology

Volumn 15, Issue 3, 2000, Pages 881-898

  Lleonart, M E ^a   Martin Duque, P ^a   Sanchez Prieto, R ^a   Moreno, A ^a   Ramon y Cajal, S ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Carcinogenesis; Heterogeneity; Radioresistance; Review; Tumor

Indexed keywords

CISPLATIN; COLCHICINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; METALLOTHIONEIN; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ANTIBODY; STAUROSPORINE DERIVATIVE; VINCA ALKALOID; VIRUS PROTEIN;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL ACTIVITY; CELL HETEROGENEITY; CHEMOSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; GENE ACTIVITY; GENE AMPLIFICATION; GENE THERAPY; GENE TRANSLOCATION; HUMAN; MICROSATELLITE INSTABILITY; NONHUMAN; ONCOGENE; POINT MUTATION; RADIOSENSITIVITY; REVIEW; TUMOR; TUMOR CLASSIFICATION; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASMS;

EID: 0033931715     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (217)

1. Clues to the pathogenesis of familial colorectal cancer
2. The multidrug resistance (mdr1) gene product functions as an ATP channel
3. pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor
4. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality
5. The causes and prevention of cancer
6. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
7. Suppression of human colorectal carcinoma cell growth by wild-type p53
8. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion
9. From bench-top to bedside
10. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinomas indicate different types of tumors
11. p53 as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
12. Archival analysis of p53 genetic and protein alterations in chinese esophageal cancer
13. Molecular themes in oncogenesis
14. Open questions on p16
15. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
16. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers
17. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
18. The american cancer society challenge goals. How far cancer rates decline in the U.S. by the year 2015?
19. P53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
20. Mutations of mitotic checkpoint genes in human cancers
21. Somatic mutations and human breast cancer
22. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
23. Oncogenes and signal transduction
24. Thymocyte apoptosis induced by p53-dependent and independent pathways
25. Immunohistochemical detection of p-glycoprotein: Prognostic correlation in childhood soft-tissue sarcoma
26. Implications of the p53 tumor-suppressor gene in clinical oncology
27. Modulation of activity of the promoter of the human MDR1 gene by p53 and ras
28. Bcl-2 blocks p53-dependent apoptosis
29. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene
30. Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability
31. The radio-responsiveness of human tumours and the initial slope of the cell survival curve
32. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer
33. WAF1, a potential mediator of p53 tumor suppression
34. WAF/CIP 1 is induced in p53-mediated G1 arrest and apoptosis
35. p53 abnormalities and genomic instability in primary human breast carcinomas
36. Chronic myelogenous leukemia: Biology and therapy
37. Human cancer syndromes: Clues to the origin and nature of cancer
38. Progressing toward a molecular description of colorectal cancer development
39. A genetic model for colorectal tumorigeneris
40. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy
41. Activating mutations for transformation by p53 produces gene products that form a hsp-70-p53 complex with altered half-life
42. Phorbol esters induce multidrug resistance in human breast cancer cells
43. The human mutator gene homolog msh2 and its association with hereditary nonpoliposis colon cancer
44. Apoptosis in cancer therapy, crossing the threshold
45. Antioncogenic effect of adenovirus E1a in human tumor cells
46. Adenovirus E1a represses protease gene expression and inhibits metastasis of human cells
47. Adenovirus E1a-mediated tumor suppression by a c-erb2/neu-independent mechanism
48. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents
49. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
50. A propective study of family history and the risk of colorectal cancer
51. Colon cancer and the p53 oncogene
52. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal
53. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
54. Age-specific risks of familial prostate carcinoma: A basis for screening recommendations in high-risk populations
55. Down-regulation of bcl-2 by p53 in breast cancer cells
56. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
57. Characterization of the ATPase activity of the M1 170.000 to 180.000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells
58. The molecular basis of turcot's syndrome
59. The p21 Cdk-Interacting Protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
60. Clinical implications of the p53 tumor suppressor gene
61. Molecular mechanisms of drug resistance
62. Failure of poly (ADP-ribose) polymerase cleavage by caspases lead to induction of necrosis and enhanced apoptosis
63. Mediating of c-myc-induced apoptosis by p53
64. Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line
65. Tumor suppressor genes
66. ADN transposition by the RAG1 and RAG2 proteins: A possible source of oncogenic translocations
67. Bcl-2 is an inner mitochondrial membrane protein that blocks programed cell death
68. p53 mutations in human cancers
69. Oncogene products as therapeutic targets for cancer
70. K-ras oncogene mutations as a prognostic marker in non-small-cell lung cancer: A combined analysis of 881 cases
71. Her-2/neu- targeting gene therapy. A review
72. Cooperation between oncogenes
73. Induction and repair of DNA double-strand breaks in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc
74. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
75. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin
76. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization
77. Why is acute leukemia more common in males? A possible sex-determined risk linked to the ABO blood group genes
78. bcl-2 rearrangements in de novo diffuse large-cell lymphoma. Association with distincive clinical features
79. Short, direct repeats flanking deletions, and duplictions insertions in p53 genes in human cancers
80. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma
81. Participation of p53 protein in the cellular response to DNA damage
82. A mammalian cell-cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
83. Allelic loss in colorectal carcinoma
84. Prognostic significance of chromosome 5q and 17p allelic deletion in colorectal adenocarcinomas
85. Gatekeepers and caretakers
86. Tumor-suppressor p53: Implications for tumor development and prognosis
87. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
88. Role of the glutathione redox cycle in acquired and de novo multidrug resistance
89. Amplification of c-myc but not c-erbB-2 is associated with high proliferative capacity in breast cancer
90. Ki-ras mutations and prognosis in colorectal cancer
91. The proto-oncogene bcl-2 and its role in regulating apoptosis
92. Wild-type p53 is a cell-cycle checkpoint determinant following irradiation
93. Bcl-2 family proteins and leukemia. Minireview
94. Viability of wild-type p53-containing and p53-deficient tumor cells following anticancer treatment: The use of papillomavirus E6 to target p53
95. Genotyping by mass spectrometric analysis of short DNA fragments
96. MDM2 gene amplification in metastatic osteosarcoma
97. P53 the guardian of the genome
98. T antigen is bound to a host protein in SV-40 transformed cells
99. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas
100. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
101. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches
102. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
103. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
104. Genetic instability in colorectal cancers
105. Genetic instability in human cancers
106. p21/cip1 is not required for the early G2 checkpoint reponse to ionizing radiation
107. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21
108. Growth suppression of human head and neck cells by introduction of a wild-type p53 gene via a recombinant adenovirus
109. K-ras and p53 mutations in hereditary non-polyposis colorectal cancers
110. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1a and accompanies apoptosis
111. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs
112. p53 is required for radiation-induced apoptosis in mouse thymocytes
113. p53 status and the efficacy of cancer therapy in vivo
114. Differential induction of transcriptionally active p53 following UV or ionizing radiation defects in chromosome instability syndromes
115. Biologia del cancer de colon e importancia de oncogenes y genes supresores
116. Genetic instability correlates with tumor size and mutant p53 with lymph node metastasis in right colon cancer
117. Frameshift mutator mutations
118. Oncogenes and cellular sensitivity to radiotherapy. A study on murine keratinocytes transformed by v-H-ras, v-myc, neu, adenovirus E1a and p53 mutant
119. p53 expression and prognosis in gastric carcinoma
120. Repair defect in p21 WAF1/CIP1 -/- human cancer cells
121. Actual causes of death in the United States
122. Expression of wild-type p53 stimulates an increase in both Bax and Bcl-xL protein content in HT29 cells
123. Cooperation between mutant p53 and the ras, raf, erb-2 and fgf-3 oncogenes for transformation of mammary cells
124. Relation of apoptosis to cancer therapy
125. ERBB-2, (HER-2/NEU) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix
126. Inhibition of multidrug resistance by a new staurosporine derivate, Na-383 in vitro and in vivo
127. Tumor suppressor p53 is a regulator of bcl-2 and Bax gene expression in vitro and in vivo
128. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
129. Antitumor activity of a phosphorothiate antisense oligodeoxy-nucleotide targeted against C-raf kinase
130. Interaction of adenoviral proteins with pRB and p53. Review
131. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy
132. Biomarkers for biological agents
133. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes
134. Oncoprotein mdm-2 conceals the activation domain of tumor suppressor p53
135. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death
136. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesion and reduced drug accumulation
137. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpression metastatic breast cancer refractory to chemotherapy treatment
138. Expression of the p53 tumor suppressor gene is a determinant of chemosensitivity
139. Bcl-2 protein in non-small-cell lung carcinoma
140. Tumour suppressor genes. No room at the p53 inn
141. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
142. Molecular diagnosis of familiar adenomatous polyposis
143. Chromosomal translocations in human cancer
144. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
145. Patologia molecular tumoral. Consideraciones generales
146. Transcriptional activation by wild-type, but not transforming, mutant of the p53 antioncogene
147. Antisense-mediated inhibition of bcl-2 protooncogene expression on leukemic cell growth and survival. Comparison of phosphodiester and phosphotiroate oligodeoxinucleotide
148. Drug resistance, oncogenes, and anti-oncogenes in epithelial tumors
149. Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognosis significance
150. Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes
151. Lack of correlation between p53 protein level and sensitivity to DNA-damaging agents in keratinocytes carrying adenovirus E1a mutants
152. Lack of correlation between p53 protein level and sensitivity to DNA-damaging agents in keratinocytes carrying adenovirus E1a mutants
153. Carcinoma cell lines become sensitive to DNA-damaging agents after infection with the adenovirus E1a
154. An association between viral genes and human oncogenic alterations: The adenovirus E1a induces the Ewing tumor fusion transcript EWS-FLI1
155. p53 germline mutations in Li-Fraumeni syndrome
156. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells
157. Ras enhances myc protein stability
158. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma
159. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene
160. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis
161. Mutations of ras genes are relatively frequent in Japanese prostate cancers, pointing to genetic differences between populations
162. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
163. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells
164. Increased resistance to cis-Diamminedichloro platinum (II) in NIH 3T3 cells transformed by ras oncogenes
165. Ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation
166. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc
167. Studies of the HER2/Neu proto-oncogene in human breast and ovarian cancer
168. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage
169. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage
170. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-exact
171. Multifactorial analysis of p53 alterations in human cancer. A review
172. Why are some tumors more radiosensitive than others?
173. E1a and tubulin
174. Oncogenic activation of p185 neu stimulates tyrosine phosporylation in vivo
175. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2
176. Overexpression of Bcl-xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis
177. P53-dependent apoptosis suppresses tumor growth and progression in vivo
178. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: Implications for clinical predisposition testing
179. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
180. Apoptosis in the pathogenesis and treatment of disease
181. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers
182. Screening for colorectal cancer
183. p53 and K-ras gene mutations correlate with tumor aggressiveness, but are not of routine prognosis value in colorectal cancer
184. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein
185. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER2/Neu gene expression, but not with ras mutations
186. Correlation between intrinsic chemoresistance her2-neu expression, p53 gene mutations, and cell proliferation chararcteristic in non-small-cell lung cancer cell lines
187. Cloning of the chromosome breakpoint of the neoplasic B cell with the t(14:18) translocation
188. Involvement of the bcl-2 gene in human follicular lymphoma
189. The growth and progression of human tumors. Implications for management strategy
190. Human cancer natural history, radiation-induced immunodepression and post-operative radiation therapy
191. Chemosensitization of HER2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A
192. Expression of full length cDNA for human MDR1 gene confers resistance to colchicine, doxorrubicine and vinblastine
193. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test
194. Altered metabolism of gluthatione in cells transformed by oncogenes which cause resistance to ionizing radiation
195. A deadly inheritance
196. p53 function and dysfunction
197. Has the breast-cancer gene been found?
198. Genetic alterations during colorectal-tumor development
199. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
200. Cell-cycle arrest versus cell death in cancer therapy
201. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB
202. Tumor suppressor genes
203. Tumor cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression
204. Estrogen and progesterone receptors and c-erb-2 oncoprotein analysis in pure in situ breast carcinoma: An immunohistochemical study
205. Cell cycle-dependent expression of cyclin D1 and a 45 kD protein in human A549 lung carcinoma cells
206. Adenovirus-mediated wilt-type p53 induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
207. p53-mediated cell death: Relationship to cell-cycle control
208. Adenovirus type 5 E1a gene products act as transformation suppressor of the neu oncogene
209. Reexpression of neu-encoded oncoprotein counteracts the tumor suppressing but not the metastasis-suppressing function of E1a
210. Liposome-mediated in vivo E1a gene transfer suppresses dissemination of ovarian cancer cells that overexpress HER-2/neu
211. A comparision of the biological activities of wild-type and mutant p53
212. The core promoter region of the p-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53
213. Somatic genetic alterations (Ioh) in benign, borderline and invasive ovarian tumors: Intratumoral molecular heterogeneity
214. Sensitization of HER-2/neu overexpressing non-small cell lung cancer cells to chemotherapy drugs by tyrosine-kinase inhibitor emodin
215. Her-2/neu-targeting cancer therapy via adenovirus-mediated E1a delivery in an animal model
216. Induction of cellular p53 activity by DNA-damaging agents and growth arrest